American Society of Clinical Oncology (ASCO) 2024

May 31 - June 4, 2024

Olaparib Durvalumab
Datopotamab Deruxtecan
Osimertinib
Capivasertib
Trastuzumab Deruxtecan
Acalabrutinib
AZD0901
AZD0901 AZD5863 AZD6422 AZD4360
AZD0901 Sabestomig Rilvegostomig Volrustomig
AZD5851
Durvalumab
Durvalumab Monalizumab Oleclumab
Durvalumab Tremelimumab
Olaparib
Rilvegostomig Volrustomig
Volrustomig

pdf

Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status

pdf

Safety + tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients (pts) with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial

PDF

ICARUS-LUNG01: A phase 2 study of datopotomab-deruxtecan (Dato-DXd) in previously treated advanced non-small cell lung cancer (NSCLC) patients, with sequential tissue biopsies and biomarkers analysis to predict treatment outcome

pdf

Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small-cell lung cancer (aNSCLC); subgroup analysis from TROPION-Lung02

ppt

Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05

pdf

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study

pdf

Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd)

PDF

Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.

pdf

Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR mutated (EGFRm) stage IB–IIIA non-small-cell lung cancer (NSCLC)

pdf

Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+/HER2- metastatic breast cancer (mNC) in the US

pdf

Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02

pdf

Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06)

pdf

A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study)

pdf

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)

pdf

Trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02

pdf

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study

pdf

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

pdf

Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03

pdf

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03

pdf

Real-world risk of bleeding events in BTKi-treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

pdf

A phase 1 trial of claudin 18.2-specific antibody drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer

pdf

CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors

pdf

CLDN18/CLDN18.2 IHC assay comparison (SP455, 43-14A, EPR19202) and co-prevalence expression with other biomarkers in gastric carcinoma

pdf

GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers

pdf

ATHENA: A phase 1/2 study of AZD5851, a chimeric Antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent HEpatocellular carciNomA (HCC)

pdf

Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)

pdf

Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma

pdf

Outcomes with perioperative durvalumab (D) in patients (pts) with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN

pdf

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

pdf

Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small-cell lung cancer (uNSCLC)

pdf

T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC)

pdf

TRITON: Phase 3b study of durvalumab (D) + tremelimumab (T) versus pembrolizumab (P) in combination with chemotherapy (CT) in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and/or KEAP1 and/or KRAS mutations

pdf

Real-world tumor BRCA testing patterns and PARP inhibitor use in HER2-negative metastatic breast cancer

pdf

GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers

pdf

eVOLVE-HNSCC: A global phase 3 study of volrutomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma following definitive concurrent chemoradiotherapy

pdf

eVOLVE-Lung02: A phase 3 study of first-line (1L) volrutomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell expression <50%

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão